Alnylam Pharmaceuticals, Inc.
A biopharmaceutical company that makes RNAi therapeutics — medicines that "silence" disease-causing genes — with six marketed drugs including ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO for rare conditions like ATTR amyloidosis. Founded in 2002 by Nobel laureate Phillip Sharp and fellow scientists, its name comes from Alnilam, the bright center star of Orion's belt, chosen as an "aspirational North Star" for genomic medicine. Its ONPATTRO was the first RNAi drug ever approved by the FDA, in 2018.
Granted 41.3K · Sold 41.3K
Granted 298.8K · Sold 187.5K
Granted 69.6K · Sold 23.7K
Granted 51.7K · Sold 19.2K
Granted 53.3K · Sold 52.5K
Granted 45.2K · Sold 43.7K
Granted 54.1K · Sold 30.2K
Granted 116.1K · Sold 101.8K
Granted 67.6K · Sold 59.9K
Granted 14.6K
Sold 3.9K
Granted 8.0K
Granted 53.1K · Sold 51.7K
Granted 6.1K · Sold 1.9K
Granted 1.4K
Granted 1.4K
Granted 19.4K · Bought 36 · Sold 18.0K
Granted 1.4K
Granted 1.4K
Granted 775
Granted 671
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Sharp Phillip ADirector · 9 transactions | -7.1% | 278.1Kas of Jan 2025 | 41.3K | — | 41.3K |
| Greenstreet YvonneChief Executive Officer, Director · 169 transactions | +177.3% | 98.8K | 298.8K | — | 187.5K |
| Poulton Jeffrey V.EVP, Chief Financial Officer · 127 transactions | +237.4% | 63.2K | 69.6K | — | 23.7K |
| Tanguler TolgaEVP, Chief Commercial Officer · 118 transactions | +987.1% | 34.3K | 51.7K | — | 19.2K |
| Bonney Michael WDirector · 20 transactions | +56.5% | 32.1Kas of Aug 2025 | 53.3K | — | 52.5K |
| Pyott David E IDirector · 16 transactions | +7% | 30.0K | 45.2K | — | 43.7K |
| Schulman Amy WDirector · 10 transactions | +17583.1% | 24.0K | 54.1K | — | 30.2K |
| Garg PushkalEVP Chief R&D · 178 transactions | +320.3% | 21.1K | 116.1K | — | 101.8K |
| Fitzgerald Kevin JosephCSO & EVP, Head of Research · 167 transactions | — | 21.1K | 67.6K | — | 59.9K |
| Supran BryanEVP, CLO and Secretary · 2 transactions | — | 14.6K | 14.6K | — | — |
| McLaughlin MelissaChief Human Resources Officer · 14 transactions | — | 13.4K | — | — | 3.9K |
| Hesslein Robert W.EVP, CLO and Secretary · 2 transactions | — | 8.0Kas of Mar 2025 | 8.0K | — | — |
| Ausiello Dennis ADirector · 28 transactions | +39.8% | 5.1K | 53.1K | — | 51.7K |
| Franchini Indrani LallEVP, CLO & Secretary · 10 transactions | — | 4.1Kas of Feb 2024 | 6.1K | — | 1.9K |
| Sigal Charles ElliottDirector · 2 transactions | — | 3.4K | 1.4K | — | — |
| Hamburg Margaret ADirector · 2 transactions | +1063.2% | 1.6K | 1.4K | — | — |
| Reitan Colleen FDirector · 22 transactions | — | 1.4K | 19.4K | 36 | 18.0K |
| Brandicourt OlivierDirector · 2 transactions | — | 1.4K | 1.4K | — | — |
| Kellogg Peter NDirector · 2 transactions | — | 1.4K | 1.4K | — | — |
| Bertozzi Carolyn RDirector · 1 transaction | — | 775as of May 2025 | 775 | — | — |
| Arbuckle Stuart ADirector · 1 transaction | — | 671 | 671 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -635.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.